Adagene Inc. Overview
Pro stress-test →Adagene is a biotechnology company developing novel antibody-based cancer immunotherapies, combining computational biology and artificial intelligence to design antibodies addressing unmet patient needs. The company leverages a proprietary AI-powered DPL (Dynamic Precision Library) platform that explores dynamic conformational diversity of protein sequences as a new paradigm for antibody drug discovery.
Strategic Profile
Pro stress-test →Adagene's highly differentiated pipeline features novel immunotherapy programs powered by its DPL platform, composed of NEObody, SAFEbody™, and POWERbody™ technologies. The company recently expanded its partnership with Sanofi with a strategic investment of up to $25 million to fund development of ADG126, its masked anti-CTLA-4 program, through a randomized Phase 2 trial in microsatellite stable colorectal cancer.
Competitive Landscape
Pro stress-test →Adagene competes in the antibody immunotherapy space against companies developing novel cancer treatments. The company differentiates through its AI-powered DPL platform and multi-technology approach (NEObody, SAFEbody, POWERbody). Strategic partnerships with major pharma (Sanofi, Merck, Exelixis, ADC Therapeutics) indicate competitive strength, though development programs remain largely in clinical stages.
Industry Context
Adagene Inc. operates in Biopharmaceutical - Oncology Immunotherapy.
Key facts
Founded: 2011 · Headquarters: Suzhou, China · Revenue: $50M-$100M